{
    "id": 22998,
    "fullName": "EGFR R451C",
    "impact": "missense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR R451C lies within the extracellular domain of the Egfr protein (UniProt.org). R451C results in reduced Egfr affinity for Egf binding in cell culture in one study (PMID: 26843189) and therefore, is predicted to lead to a loss of Egfr protein function.",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "R451C",
    "createDate": "06/01/2016",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 135848,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55160191C>T",
        "cDna": "c.1351C>T",
        "protein": "p.R451C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6628,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23657,
                "profileName": "EGFR R451C"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6627,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23657,
                "profileName": "EGFR R451C"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6626,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23657,
                "profileName": "EGFR R451C"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR R451C in culture (PMID: 26888827).",
            "molecularProfile": {
                "id": 23657,
                "profileName": "EGFR R451C"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7071,
                    "pubMedId": 26888827,
                    "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26888827"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23657,
            "profileName": "EGFR R451C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135850,
            "transcript": "NM_201282",
            "gDna": "chr7:g.55160191C>T",
            "cDna": "c.1351C>T",
            "protein": "p.R451C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135849,
            "transcript": "NM_201284",
            "gDna": "chr7:g.55160191C>T",
            "cDna": "c.1351C>T",
            "protein": "p.R451C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135848,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55160191C>T",
            "cDna": "c.1351C>T",
            "protein": "p.R451C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}